

CLINICALTRIALS.GOV NU RECORD REVIEW

PROTOCOL ID	RECORD OWNER	REVIEWER	<input type="checkbox"/> Registration <input type="checkbox"/> Update status <input type="checkbox"/> Results <i>(add Results checklist)</i>	<input type="checkbox"/> pACT/ACT <input type="checkbox"/> Non-ACT
NCT#				
DATE RELEASED	COMMENTS DATE	REPLY DATE	DATE PUBLISHED	
GENERAL REVIEW ITEMS			NOTES	
<ul style="list-style-type: none"> <input type="checkbox"/> If study has any grant funding, information provided should match what is on the grant application <input type="checkbox"/> Record Owner is the PI or Coordinator – Admin Only <input type="checkbox"/> Contact info for Record Owner is up to date <input type="checkbox"/> PI on record matches IRB PI: _____ <input type="checkbox"/> NCT# included in IRB “Clinical Trials Information” section <input type="checkbox"/> All Warnings/Errors addressed <input type="checkbox"/> All parenthetical citations have been removed <input type="checkbox"/> All acronyms have been expanded on their first use <input type="checkbox"/> Spell-check complete <input type="checkbox"/> Free-text fields are blank if there is no information to report, and do not contain text such as “TBD,” “Pending,” “N/A,” “None” 				
PROTOCOL SECTION				
STUDY IDENTIFICATION				
<ul style="list-style-type: none"> <input type="checkbox"/> Unique protocol ID is the IRB# <input type="checkbox"/> Brief Title does not include study type (e.g., Phase I, Randomized...) <input type="checkbox"/> Official title should match what is in the IRB (or grant application if applicable) <input type="checkbox"/> Secondary IDs include NIH grant #s (verify in IRB), and IRB# 				
STUDY STATUS				
<ul style="list-style-type: none"> <input type="checkbox"/> Record Verification Date is the current month/year <input type="checkbox"/> Overall Status matches IRB/CRMS <input type="checkbox"/> Study start date verified with CRMS enrollment date <input type="checkbox"/> Completion Dates Actual/Anticipated have been evaluated for accuracy <input type="checkbox"/> If timeframes for outcomes are the same the primary and study completion dates are identical 				
SPONSOR/COLLABORATORS				
<ul style="list-style-type: none"> <input type="checkbox"/> Responsible Party: Principal Investigator <input type="checkbox"/> All sources of support identified in IRB “Support Information” section included as Collaborators <input type="checkbox"/> Full Name used and if not recognized, “Recognize” is selected 				
OVERSIGHT				
<ul style="list-style-type: none"> <input type="checkbox"/> IND/IDE information completed (if applicable) 				
STUDY DESCRIPTION				
<ul style="list-style-type: none"> <input type="checkbox"/> Brief Summary does not unnecessarily duplicate information provided for other data elements <input type="checkbox"/> Brief Summary clearly states the study’s hypothesis or the purpose (for interventional and observational) <input type="checkbox"/> Brief Summary and Detailed Description are written in complete sentences with no formatting errors <input type="checkbox"/> Record does not use personal pronouns: “I, we, our, us, they, them, their” – becomes “the investigator(s)”; “you, your” – becomes “the participant(s)” 				

CONDITIONS

- Conditions/Focus of study are discrete and does not use verbs or complete sentences
- Keywords are not numbered or bulleted, each condition and keyword is listed individually, one per line

STUDY DESIGN

- All required fields are completed
- Verify Study Design based on protocol in IRB
- "Allocation" marked as "N/A" for single-arm interventional studies
- Enrollment number Actual/Anticipated verified

ARMS/INTERVENTIONS

- Arm Title or Group/Cohort Label is brief and informative (even if there is only 1 arm)
- Interventions and intervention descriptions are entered correctly
- Arms/interventions are cross-referenced appropriately

OUTCOME MEASURES

- Title is specific and states WHAT is being measured, only 1 variable must be assessed per outcome measure
- Description explains WHAT is being measured, not WHY it is being measured
- Scoring scale name, score range, significance of upper and lower limits specified (if applicable)
- Unit of measure specified
- Time frame specified as a single time point or change between 2 time points

INCORRECT: "Safety and Toxicity", Description: "Safety of study drug."

CORRECT: "Safety as assessed by number of participants experiencing adverse events" Description: "Number of participants experiencing adverse events grade 3 or higher, as defined by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)"

ELIGIBILITY

- Age Limits are consistent with the Eligibility Criteria and with other parts of the record
- Eligibility criteria is divided into Inclusion/Exclusion criteria in bulleted format

CONTACTS/LOCATIONS

- Central Contact Person specified and accurate
- Study Officials match IRB
- All study sites specified matches CRMS
- Recruiting status for each study site accurate (if at least one study site is recruiting then Study Status reflects "Recruiting")
- Each facility is listed in a separate field

IPD Sharing Statement

- The Plan to Share IPD selection is consistent with the IPD Sharing Plan Description.

REFERENCES

- Each citation is listed in a separate field (if applicable)

Add results checklist if results entry submitted.

RESULTS SECTION

PARTICIPANT FLOW

- Protocol Enrollment refers to total number of subjects who consented to protocol (including screen failures, withdrawals, etc.)
- Recruitment details (optional) explains any specifics used at time of recruitment
- Pre-assignment details explains (in detail) what happened to subjects who signed consent but were not assigned to an arm/intervention (i.e., how many screen failures, withdrawals, etc.)
- Arms and arm descriptions specified consistent with protocol section
- Number of Participants Started refers to total number of participants assigned to each arm
- Number of Participants Completed refers to total number of participants who completed study intervention
- Reason(s) for Not Completed provided
- Divided into periods/milestones appropriately
- Total number of participants started cannot be greater than enrollment number
- Total number completed is equal to or less than “started”

BASELINE CHARACTERISTICS

- Overall Number of Baseline Participants should match Number of participants Started (from Participant Flow)
- Baseline Analysis Population Description explains if there is a discrepancy between Overall & Started numbers
- Arm titles/descriptions are consistent with participant flow and/or protocol section
- Data is presented per arm
- If “number of participants” is reported, make sure Measure Type is “Count of Participants”
- Measure description is specified for all Study-specific measures

OUTCOME MEASURES

- Titles/descriptions/time frame meet the criteria (as specified on prior checklist)
- Results are reported per arm
- Analysis Population Description includes reason why Number of Participants analyzed is different than total number of participants completed (if applicable)
- Type and Number of Units analyzed is indicated, if other than “number of participants” (i.e., # of Lesions)
- Unit of measure matches what is stated in Outcome Title/Description
- Sum of all results entered for each arm equals overall number of participants analyzed
- Verify true data is entered and there are no placeholders
- Statistical Analysis portion is optional

ADVERSE EVENTS

- Time frame specified
- Collection Approach specified
- Arm titles/descriptions consistent with other sections in the record
- Data presented per arm
- All-cause mortality specified (cross-check with number “not completed due to death” from participant flow and any mortality measures in outcome section, if applicable)
- Total Number “At Risk” must be equal to total number of participants who started the study

CERTAIN AGREEMENTS

- Principal Investigators are employed by the organization sponsoring the study

RESULTS POINT OF CONTACT

- Information is correct and valid email address/phone number entered

DOCUMENT SECTION

- Protocol (required for primary completion date after January 18, 2017)
- Statistical Plan (required for primary completion date after January 18, 2017)
- Informed Consent Form (required for studies approved on or after January 21, 2019)
- Cover Page
 - Record (NCT) Number
 - Study Title
 - PI Name
 - Date of Document (must match date within actual document)
- Additional Documents: _____

REFERENCES

- Links are verified (if applicable)